Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2024-12-18 | New | Yet to Sell | $0 | Equity and Debt | 04 06c | SEC link |
| 2024-05-24 | Amended | $2,577,000 | $148,000 | Equity and Debt | 06b | SEC link |
| 2024-05-24 | New | Yet to Sell | $0 | Equity and Debt | 06c | SEC link |
| 2024-02-26 | Amended | $2,429,000 | $1,769,000 | Equity and Debt | 06b | SEC link |
| 2023-08-29 | Amended | $660,000 | $660,000 | Equity and Debt | 06b | SEC link |
| 2023-05-08 | New | Yet to Sell | $0 | Equity and Debt | 06b | SEC link |
| Name | Role |
|---|---|
| Albert Di Rienzo | Director, Executive |
| Carl Eckstein | Director |
| Michael Stanfield | Director |
| Mark Wang | Director |